SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cell combo shows promise in tough head and neck cancers
Disease control CompletedThis early-phase trial tested a new approach for people with advanced head and neck cancer that has come back or spread. It combined specially trained natural killer (NK) immune cells with drugs that help the immune system attack cancer. The study enrolled 11 participants to chec…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy drug may delay return of aggressive head and neck cancers
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab for one year after standard treatment could help prevent head and neck cancer from coming back in 100 patients at high risk for recurrence. Participants received either pembrolizumab or a placebo. The main goal…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy combo shows promise in reducing head and neck cancer recurrence
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard surgery, radiation, and chemotherapy could help prevent head and neck cancer from coming back. The study enrolled 67 adults with advanced, surgically removable head and neck squam…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to boost Radiation's punch against head and neck cancer
Disease control CompletedThis early-stage study tested the safety of adding the drug afatinib to standard radiation therapy for people with head and neck cancer at risk of recurrence. Afatinib blocks proteins that help cancer grow and may make cancer cells more sensitive to radiation. The study included …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to cut side effects in head and neck cancer
Disease control CompletedThis study tested a three-step treatment for head and neck cancer that uses chemotherapy before surgery, then adjusts further treatment based on risk. The goal was to see if this personalized approach could reduce side effects while still controlling the cancer. 40 adults with a …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Drug combo shows promise for Tough-to-Treat cancers
Disease control CompletedThis study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Radiation boost may help immunotherapy work better in advanced cancers
Disease control CompletedThis study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: John L. Villano, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedThis phase II trial tested whether adding sorafenib to cetuximab works better than cetuximab alone for patients with advanced head and neck cancer that has come back or spread. Fifty-five adults with various types of head and neck cancer took part. The study measured how long pat…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
MRI-Guided radiation boost shows promise for tough head and neck cancers
Disease control CompletedThis phase 2 trial tested whether giving an extra dose of radiation to the most resistant parts of a tumor, identified by a special MRI scan (DCE-MRI), could improve outcomes for people with advanced head and neck cancer. 106 participants received standard chemoradiation (cisplat…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a smart antibody boost chemo for head and neck cancer?
Disease control CompletedThis phase 3 trial tested whether adding a targeted antibody (cetuximab) to standard chemotherapy (cisplatin) helps people with advanced head and neck cancer that has spread or come back. About 120 patients received either cisplatin plus cetuximab or cisplatin plus a placebo. The…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered T-Cells take aim at bladder, skin, and head and neck cancers
Disease control CompletedThis early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Tailored drug combo tested for tough head and neck cancers
Disease control CompletedThis phase II trial tested a personalized approach for people with advanced head and neck cancer that had stopped responding to prior immunotherapy. Researchers used genetic testing to choose which drug to add to nivolumab—either relatlimab or ipilimumab. The study enrolled 20 pa…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo shows promise against tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental combo targets Hard-to-Treat head and neck cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs — IRX-2 and durvalumab — in 19 people with advanced head and neck cancer that could not be cured by standard treatments. The goal was to see if the combination was safe and could boost the immune response inside tumors. The…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Old chemo drug gets new look for tough head and neck cancers
Disease control CompletedThis phase 2 trial tested the chemotherapy drug mitomycin C in 48 patients with incurable head and neck cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. Researchers hope to find a new option for patients with very lim…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug INCA32459 enters early human testing
Disease control CompletedThis early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a vaccine stop head and neck cancer from coming back?
Disease control CompletedThis study tested a vaccine called PepCan in 17 people who had head and neck cancer and were in remission. The goal was to see if the vaccine is safe and can reduce the chance of the cancer returning. Participants received seven injections of either PepCan or a placebo over about…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immunotherapy boosts standard treatment for head and neck cancer in early trial
Disease control CompletedThis early-phase trial tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation is safe and effective for people with advanced head and neck cancer. 59 participants received pembrolizumab before, during, and after their regular treatment. The goal was…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Sanford Health • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug cocktail aims to revive immune attack on head and neck tumors
Disease control CompletedThis early-phase study tested a combination of two drugs—oral decitabine and durvalumab—in 13 adults with advanced head and neck cancer that had stopped responding to standard immunotherapy. The goal was to see if the combo could safely boost the immune system's ability to fight …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:40 UTC
-
New drug cocktail shows promise for tough head and neck cancer
Disease control CompletedThis early-phase study tested combinations of immunotherapy drugs (atezolizumab and tiragolumab) plus chemotherapy (carboplatin and paclitaxel) in 12 people with advanced head and neck cancer that had not been treated before. The goal was to see if these combinations could comple…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 26, 2026 17:21 UTC
-
Dietitian home visits may boost quality of life in head and neck cancer patients
Symptom relief CompletedThis study tested whether having a dietitian visit patients at home during radiotherapy could improve their quality of life. 117 adults with head and neck cancer took part. The goal was to see if personalized nutrition advice helps patients cope better with treatment side effects…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: NA • Sponsor: University Hospital, Caen • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Red light may soothe radiation mouth sores
Symptom relief CompletedThis study tested whether shining a red LED light on mouth sores caused by radiation therapy can help them heal. 28 people with head or neck cancer who already had mild sores received a 7-minute light treatment before each radiation session. The main goal was to see if the sores …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Medical cannabis studied as supportive care for head and neck cancer patients
Symptom relief CompletedThis study looked at whether head and neck cancer patients would use medical cannabis to help with side effects during chemotherapy and radiation. 30 patients were observed to see how many signed up for and obtained medical cannabis. The goal was to understand if cannabis could b…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Home workouts may ease side effects of head and neck cancer radiation
Symptom relief CompletedThis study looked at whether a home-based exercise program can help people with head and neck cancer maintain movement, muscle strength, and posture while undergoing radiation therapy. Twenty-four adults who had surgery and were scheduled for radiation took part. The goal was to …
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: NA • Sponsor: Burak Ertürk • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New radiation planning method aims to spare head and neck cancer patients from dry mouth
Symptom relief CompletedThis pilot study tested two different methods of planning radiation therapy for head and neck cancer: margin-based and robust planning. The goal was to see which method causes less dry mouth, a common side effect. Twenty-three patients participated, and researchers measured dry m…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: NA • Sponsor: University of Arkansas • Aim: Symptom relief
Last updated Jun 26, 2026 12:40 UTC
-
New study explores what matters most to patients with high-risk head and neck skin cancer
Knowledge-focused CompletedThis study looked at how 78 patients with high-risk skin cancer on the head or neck felt about their treatment decisions, quality of life, and satisfaction with care. Researchers used standard questionnaires to measure these factors at two points: right after a team of doctors di…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC